| 摘要 |
The present invention relates to methods and compositions for regulating lectin complement pathway (LCP)-associated complement activation. In particular, the invention relates to methods and compositions for inhibiting LCP-associated complement activation in order to inhibit hyperglycemic myocardial damage. The invention also relates to the treatment of cardiomyopathy and/or hypertrophy, such as cardiac hypertrophy. The invention also relates to methods and compositions for inhibiting the loss of cardiac progenitor cells by inhibiting LCP-associated complement activation. The methods include both in vitro and in vivo methods. The methods can be accomplished by contacting a mammalian cell having a surface exposed mannose binding lectin (MBL) ligand, such as a cardiac cell, with an effective amount of a MBL inhibitor to inhibit LCP-associated complement activation. |
